Videregen’s goal is to offer the world’s first commercially available organ replacement products to address the chronic shortage of organs for transplantation.
Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient’s own stem cells are added, creating a bespoke organ replacement.
Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world’s first commercially available organ replacements for these conditions, reducing healthcare costs and improving the quality of life for patients.
There is a worldwide shortage of donor organs for transplantation and an emergent need to extend transplant availability and for regenerative therapies to restore organ function, increase quality and length of life and reduce healthcare costs.
|Product||Life Science EIS|
|Aim of funding||Growth|
|HMRC Advanced Assurance received||Yes|
|Envisaged investor exit||4-5 Years|
|Targeted return||In excess of 4x capital invested|